Celcuity Plans To Initiate Phase 3 Clinical Trial To Evaluate Gedatolisib Plus CDK4/6 Inhibitor And Fulvestrant; Enters Amendment To Existing Debt Facility Agreement
Portfolio Pulse from Benzinga Newsdesk
Celcuity plans to initiate a Phase 3 clinical trial to evaluate Gedatolisib in combination with a CDK4/6 inhibitor and Fulvestrant. Additionally, the company has amended its existing debt facility agreement, securing an additional term loan of approximately $62 million.
May 30, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celcuity is set to begin a Phase 3 clinical trial for Gedatolisib in combination with a CDK4/6 inhibitor and Fulvestrant. The company also secured an additional $62 million through an amended debt facility agreement.
The initiation of a Phase 3 clinical trial is a significant milestone for Celcuity, potentially leading to new treatment options and revenue streams. The additional $62 million in funding strengthens the company's financial position, supporting its R&D efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100